Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

916
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
916
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

743
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
743
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.5K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.5K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.3K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.5K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.5K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

363
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
363

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

To adopt or adapt an existing COS for neonatal research: qualitative study.

Trials·2026
Same author

National guideline development and adaptation, Egypt.

Bulletin of the World Health Organization·2026
Same author

Persistent physical symptoms not explained by structural abnormalities or disease processes: a primary care approach to promote recovery.

Scandinavian journal of primary health care·2026
Same author

Expert stakeholders on the role of qualitative research in World Health Organisation guidelines.

Health policy and planning·2026
Same author

How "Global" are Globally Oriented Pulmonary Rehabilitation Studies? Strategies to Promote Equitable Participation From Low- and Middle-Income Countries: A Systematic Review.

Journal of cardiopulmonary rehabilitation and prevention·2025
Same author

Experiences of Female Rugby Union Players and Practitioners in Rehabilitation Following a Shoulder Injury.

Sports (Basel, Switzerland)·2025
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Apr 11, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K

Directly observed therapy for treating tuberculosis.

Jamlick Karumbi1, Paul Garner

  • 1SIRCLE collaboration, KEMRI-wellcome Trust Research Programme, Kenyatta National Hospital Grounds, P.O. Box 43640 ? 00100, Nairobi, Kenya.

The Cochrane Database of Systematic Reviews
|May 30, 2015
PubMed
Summary
This summary is machine-generated.

Directly Observed Therapy (DOT) for tuberculosis (TB) treatment did not significantly improve cure rates or treatment completion compared to self-administered therapy. Policymakers should explore alternative strategies beyond direct observation for TB management.

More Related Videos

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.8K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K

Related Experiment Videos

Last Updated: Apr 11, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.4K
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.8K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.3K

Area of Science:

  • Public Health and Epidemiology
  • Infectious Disease Management
  • Clinical Trial Analysis

Background:

  • Tuberculosis (TB) treatment necessitates a minimum of six months of therapy to ensure cure and prevent drug resistance.
  • Incomplete TB treatment poses risks of treatment failure and the development of multidrug-resistant tuberculosis.
  • Directly Observed Therapy (DOT) is a WHO-endorsed strategy involving supervised medication intake to enhance patient adherence.

Purpose of the Study:

  • To systematically evaluate the efficacy of Directly Observed Therapy (DOT) versus self-administered therapy for active TB treatment and prophylaxis.
  • To compare the outcomes of various forms of DOT implementation.
  • To assess the impact of DOT on tuberculosis cure rates and treatment completion.

Main Methods:

  • Conducted a systematic review of randomized controlled trials (RCTs) and quasi-RCTs comparing DOT with self-administration for TB treatment or prophylaxis.
  • Searched multiple databases (Cochrane, MEDLINE, EMBASE, LILACS, mRCT) up to January 2015, including reference checking and expert contact.
  • Independently assessed risk of bias, extracted data, and compared interventions using risk ratios (RR) with 95% confidence intervals (CI), employing random-effects models and GRADE assessment.

Main Results:

  • Eleven trials with 5662 participants were included; DOT did not substantially improve TB cure rates (RR 1.08, 95% CI 0.91 to 1.27) or treatment completion (RR 1.07, 95% CI 0.96 to 1.19) compared to self-administration.
  • Daily DOT showed a potential benefit in TB cure only when compared to monthly clinic visits in the self-administered group; this effect diminished with more frequent contact in the control arm.
  • No significant differences in cure or treatment completion were observed when comparing DOT at home versus at a health facility, or when comparing DOT administered by family members versus community health workers.

Conclusions:

  • The evidence suggests that Directly Observed Therapy (DOT) is not a definitive solution for poor adherence in tuberculosis treatment.
  • Given the substantial resource and cost implications of DOT, policymakers should consider alternative strategies to improve TB management.
  • Future approaches should address financial and logistical barriers, enhance patient and staff motivation, and improve defaulter follow-up systems.